Phase 1, QT/QTC Interval Study in Healthy Subjects
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the effect of multiple doses of lumacaftor in combination
with ivacaftor on cardiac repolarization, as detected by QT/QTc interval corrected for heart
rate in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Fluoroquinolones Ivacaftor Moxifloxacin Norgestimate, ethinyl estradiol drug combination